Phuturdex › Drugs › Clemastine Fumarate
Drugs in development · updated 30 October 2026
Clemastine Fumarate: clinical trials and development status
Other names and codes: Tavist-1
As of 30 October 2026 Clemastine Fumarate is in 8 active clinical trials (recruiting or ongoing, phases I–III) for 22 diseases. The most advanced phase is II.
Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Clemastine Fumarate and get an email at every change or safety alert.
Sign in free →Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Multiple sclerosis | II | 2 | NCT02521311 |
| Central auditory disease | I–II | 1 | NCT07304024 |
| Chronic progressive multiple sclerosis | I–II | 1 | NCT05359653 |
| Demyelinating disease | I–II | 1 | NCT06065670 |
| Depression | II | 1 | NCT06591091 |
| Developmental language disorder | I–II | 1 | NCT07304024 |
| Eye pain | II | 1 | NCT02521311 |
| Hearing disorder | I–II | 1 | NCT07304024 |
| Hearing Loss | I–II | 1 | NCT07304024 |
| Hidden hearing loss | I–II | 1 | NCT07304024 |
| Marchiafava-Bignami disease | I–II | 1 | NCT06065670 |
| Noise-induced hearing loss | I–II | 1 | NCT07304024 |
| Optic neuritis | II | 1 | NCT02521311 |
| Presbycusis | I–II | 1 | NCT07304024 |
| Relapsing-remitting multiple sclerosis | I–II | 1 | NCT05359653 |
| Schizophrenia | II | 1 | NCT06315972 |
| Sensorineural hearing loss | I–II | 1 | NCT07304024 |
| Vision disorder | II | 1 | NCT02521311 |
| Williams-Beuren syndrome | II | 1 | NCT06087757 |
| Brain Injuries | I | 1 | NCT07688746 |
| Periventricular leukomalacia | I | 1 | NCT07688746 |
| Premature Birth | I | 1 | NCT07688746 |
Everything on Clemastine Fumarate
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.